---
title: "This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290061557.md"
description: "Wall Street analysts downgraded five stocks on Wednesday: BTIG downgraded Ellington Financial (EFC) to Neutral; BofA downgraded Leidos (LDOS) to Neutral with a price target cut to $125; Goldman Sachs downgraded Ermenegildo Zegna (ZGN) to Neutral but raised its target to $14; William Blair downgraded Simulations Plus (SLP) to Market Perform; and Morgan Stanley downgraded ResMed (RMD) to Equal-Weight, lowering its target to $230."
datetime: "2026-06-17T13:13:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290061557.md)
  - [en](https://longbridge.com/en/news/290061557.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290061557.md)
---

# This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   BTIG analyst Douglas Harter downgraded **Ellington Financial Inc** (NYSE:EFC) from Buy to Neutral. Ellington Financial shares closed at $13.67 on Tuesday. See how other analysts view this stock.
-   B of A Securities analyst Mariana Perez downgraded **Leidos Holdings, Inc.** (NYSE:LDOS) from Buy to Neutral and cut the price target from $200 to $125. Leidos shares closed at $113.58 on Tuesday. See how other analysts view this stock.
-   Goldman Sachs analyst Adrien Duverger downgraded **Ermenegildo Zegna N.V.** (NYSE: ZGN) from Buy to Neutral and raised the price target from $13.3 to $14. Ermenegildo Zegna shares closed at $14.49 on Tuesday. See how other analysts view this stock.
-   William Blair analyst Max Smock downgraded **Simulations Plus, Inc.** (NASDAQ:SLP) from Outperform to Market Perform. Simulations Plus shares closed at $18.24 on Tuesday. See how other analysts view this stock.
-   Morgan Stanley analyst David Bailey downgraded **ResMed Inc.** (NYSE:RMD) from Overweight to Equal-Weight and lowered the price target from $286 to $230. ResMed shares closed at $193.94 on Tuesday. See how other analysts view this stock.

Considering buying EFC stock? Here’s what analysts think:

_Photo via Shutterstock_

### Related Stocks

- [RMD.US](https://longbridge.com/en/quote/RMD.US.md)
- [ZGN.US](https://longbridge.com/en/quote/ZGN.US.md)
- [SLP.US](https://longbridge.com/en/quote/SLP.US.md)
- [EFC.US](https://longbridge.com/en/quote/EFC.US.md)
- [LDOS.US](https://longbridge.com/en/quote/LDOS.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [RMD.AU](https://longbridge.com/en/quote/RMD.AU.md)
- [EFC-B.US](https://longbridge.com/en/quote/EFC-B.US.md)
- [EFC-A.US](https://longbridge.com/en/quote/EFC-A.US.md)
- [EFC-C.US](https://longbridge.com/en/quote/EFC-C.US.md)
- [EFC-D.US](https://longbridge.com/en/quote/EFC-D.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [ResMed beats on earnings and ups dividend, yet shares plummet](https://longbridge.com/en/news/295180735.md)
- [ResMed director Peter C. Farrell disposes of 8,000 common shares worth $1.8 million](https://longbridge.com/en/news/295133419.md)
- [Royal Bank of Canada Reduces Stock Holdings in ResMed Inc. $RMD](https://longbridge.com/en/news/294602242.md)
- [Ellington Financial Q2 adjusted EPS and net income beat estimates on Longbridge strength](https://longbridge.com/en/news/295144671.md)
- [ResMed Q4 FY26 GAAP diluted EPS rises 2% to $2.64; revenue increases 9% to $1.46 billion](https://longbridge.com/en/news/295140984.md)